Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Importantly, KRAS was proved to mediate LINC01420-facilitated PC cell proliferation.
|
31562613 |
2020 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Mu-KRAS attenuates Hippo signaling pathway through PKCι to sustain the growth of pancreatic cancer.
|
31230347 |
2020 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs.
|
30653981 |
2019 |
Pancreatic carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The aforementioned results indicate that KIS37 administration is a novel therapeutic strategy for targeting PDK4 in KRAS-activated intractable human pancreatic cancer.
|
31106493 |
2019 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Hyperinsulinemia is a risk factor for pancreatic cancer, but the function of insulin in carcinogenesis is unclear, so this study aimed to elucidate the carcinogenic effects of insulin and the synergistic effect with the KRAS mutation in the early stage of pancreatic cancer.
|
30838710 |
2019 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We conclude that EGFR-targeted RIT with panitumumab-MCP-<sup>177</sup>Lu was able to overcome resistance to panitumumab in KRAS mutant PANC-1 tumors in NRG mice and may be a promising approach to treatment of PnCa in humans.
|
30589553 |
2019 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Addition of analysis of KRAS mutation or immunohistochemistry with MUC1 and carcinoembryonic antigen improves the diagnostic performance of fine needle aspiration cytology for the diagnosis of pancreatic carcinoma.
|
30929285 |
2019 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We identified several cancer-related SAAVs including KRAS, which is an important oncoprotein in pancreatic cancer.
|
30404448 |
2019 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Further workup revealed that circulating tumor-derived DNA and liver metastases originated from a synchronous KRAS-mutated cancer of the pancreas.
|
31134762 |
2019 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Hence, simultaneously targeting both the TGF-β and KRAS pathways might dismantle the obstacles of pancreatic cancer therapy.
|
31033217 |
2019 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The same missense variants between the initial tumor and remnant PC were discovered only in KRAS of one patient, and in HRAS of one patient.
|
30515563 |
2019 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer.
|
31311847 |
2019 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The KRAS gene is the most frequently mutated gene in pancreatic cancer, and no successful anti-Ras therapy has been developed.
|
31268978 |
2019 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Importantly, T-UPSM demonstrated superior safety and antitumor efficacy over triptolide and T-NPSM in KRAS mutant pancreatic cancer mouse models.
|
30912923 |
2019 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer.
|
31406261 |
2019 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Importantly, FGTI-2734 inhibited the growth of xenografts derived from four patients with pancreatic cancer with mutant KRAS (2 G12D and 2 G12V) tumors.
|
31227505 |
2019 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Initially demonstrated in oncogenic KRAS-driven models of pancreatic cancer, macropinocytosis triggers the internalization of extracellular proteins via discrete endocytic vesicles called macropinosomes.
|
30967003 |
2019 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
PC significantly inhibited the viability of KRAS mutant pancreatic cancer cells (PANC-1 and MiaPaCa-2) in a dose-dependent manner; however, it did not affect the wild type KRAS pancreatic cancer cells (BxPC-3).
|
30716311 |
2019 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Western blot analysis revealed that LY-1816 markedly suppressed the Src signaling, and downregulated the expression of FOSL1; FOSL1 is an oncogene vulnerability in KRAS-driven pancreatic cancer.
|
30618127 |
2019 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our data suggest a crucial role of LIF in KRAS-driven pancreatic cancer and that blockade of LIF by neutralizing antibodies represents an attractive approach to improving therapeutic outcomes.
|
31296870 |
2019 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) has been depicted as a therapeutic target in pancreatic cancer for many years.
|
28639199 |
2019 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Targeting EphA2 with miR-124 mediates Erlotinib resistance in K-RAS mutated pancreatic cancer.
|
30604411 |
2019 |
Pancreatic carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
KRAS G12D point mutation plays an important role in the incidence of non-small-cell lung cancer (NSCLC) as well as colorectal cancer, pancreatic cancer and breast cancer.
|
30876538 |
2019 |
Pancreatic carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer.
|
31263025 |
2019 |
Pancreatic carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
KRAS pathway expression changes in pancreatic cancer models by conventional and experimental taxanes.
|
31375828 |
2019 |